Endologix Resumes Shipments and Procedures with AFX and Some Sizes of AFX2
December 29, 2016 09:00 ET
|
Endologix
Schedules Conference Call for December 30, 2016 at 9:00 am ET IRVINE, Calif., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for...
Endologix Announces Temporary Hold on AFX to Resolve a Manufacturing Issue
December 27, 2016 07:30 ET
|
Endologix
Conference Call Scheduled for 9:00 am ET Today, December 27, 2016 IRVINE, Calif., Dec. 27, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments...
Endologix Receives Australian Therapeutic Goods Administration (TGA) Approval for AFX®2 Bifurcated Endograft System
December 19, 2016 09:00 ET
|
Endologix
IRVINE, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the Australian Therapeutic...
Endologix to Participate at the Guggenheim Securities 4th Annual Boston Healthcare Conference
December 06, 2016 09:00 ET
|
Endologix
IRVINE, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today it will participate at the...
Positive Two-Year Data from the Nellix® EVAS FORWARD Global Registry Presented at 2016 VEITH Symposium
November 17, 2016 09:30 ET
|
Endologix
IRVINE, Calif., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of two-year...
Positive Five-Year Results from the Global Ovation® Pivotal Trial Presented at 2016 VEITH Symposium
November 16, 2016 10:00 ET
|
Endologix
IRVINE, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of positive...
Endologix Provides Update on Nellix PMA Process
November 16, 2016 09:00 ET
|
Endologix
IRVINE, Calif., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the U.S Food and Drug...
Endologix to Participate in Four Investor Conferences in November 2016
November 07, 2016 09:00 ET
|
Endologix
IRVINE, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief...
Endologix Reports Results for the Third Quarter 2016
November 01, 2016 16:05 ET
|
Endologix
IRVINE, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three...
Endologix Appoints Matthew Thompson, M.D., as Chief Medical Officer
October 25, 2016 09:00 ET
|
Endologix
IRVINE, Calif., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced the appointment of Matthew Thompson,...